IV and topical TXA superior to placebo for hematological outcomes after PLIF
Intravenous Administration of Tranexamic Acid Significantly Reduces Visible and Hidden Blood Loss Compared with Its Topical Administration for Double-Segment Posterior Lumbar Interbody Fusion: A Single-Center, Placebo-Controlled, Randomized TrialWorld Neurosurg. 2019 Feb;122:e821-e827.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
150 patients with lumbar degenerative disease and scheduled for a posterior lumbar interbody fusion procedure were randomized to receive intravenous TXA, topical TXA or placebo for blood loss. Outcomes of interest included hemoglobin, hematocrit and fibrinogen levels, prothrombin time, extubation time, hospital length of stay, post-operative Visual Analog Scale (VAS), intra-operative blood loss, d...
Join the Conversation
Please Login or Join to leave comments.